Advice
Following a full submission.
Palonosetron (Aloxi) is accepted for use within NHS Scotland for the prevention of acute nausea and vomiting associated with highly emetogenic cancer chemotherapy and the prevention of nausea and vomiting associated with moderately emetogenic cancer chemotherapy.
It is as effective as other 5HT3 antagonists in preventing emesis when given as a single intravenous injection following highly emetogenic chemotherapy (HEC) in the acute phase and moderately emetogenic chemotherapy (MEC) in the acute and delayed phases post–chemotherapy.
Download detailed advice54KB (PDF)
Medicine details
- Medicine name:
- Palonosetron 250 micrograms solution for injection (Aloxi®)
- SMC ID:
- 208/05
- Indication:
- Prevention of acute nausea and vomiting associated with highly-emetogenic cancer chemotherapy and the prevention of nausea and vomiting associated with moderately -emetogenic cancer chemotherapy
- Pharmaceutical company
- Cambridge Laboratories
- BNF chapter
- Central nervous system
- Submission type
- Full
- Status
- Accepted
- Date advice published
- 07 November 2005